Coronary Atherosclerotic Heart Disease
Conditions
Interventions
PCSK9 inhibitor combination treatment group (experimental group):Patients in the experimental group were treated with evolocumab, a PSCK9 inhibitor, in addition to their original statin (140 mg subcut
Intensive statin treatment group (control group):Patients in the control group were treated with an intensive statin or a maximum tolerated dose of statin.
Sponsors
Beijing Anzhen Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) age > 18 years old; (2) admission due to acute coronary syndrome; (3) planned to undergo CABG in Beijing Anzhen Hospital; (4) LDL-C >70 mg/dL (1.8mmol/l) after at least 4 weeks of moderate-intensity statin therapy; (5) Patients were voluntarily enrolled in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: (1) allergy to, intolerance to or contraindication to statin or Evolocumab; (2) patients previously treated with Evolocumab or ezetimibe; (3) heart failure (NYHA class III-IV) persisted after continuous therapy; (4) left ventricular ejection fraction 400mg/dL; (6) previous history of hemorrhagic stroke; (7) renal insufficiency (creatinine clearance rate < 30 mL/min); (8) life expectancy less than 1 year; (9) lactating or pregnant patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Adverse Cardiac Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Non-fatal myocardial infarction;Fatal or non-fatal ischemic stroke;Unstable angina pectoris that requires hospitalization treatment;Coronary death;Coronary artery re-revascularization ;Cardiovascular death;All-cause mortality; | — |
Countries
China
Contacts
Public ContactDongmei Shi
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University
Outcome results
None listed